We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3166)4/9/2018 10:55:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3202
Indeed, strong data for JAK1 Upadacitinib. Competition for GLPG/GILD too. Two Qs, are Humira response numbers bit on low side and why MACE/Death is pronounced in Humira/placebo? Bit biased in randomization, baseline unbalance?

OT: Nice move in QURE, too!

To: tuck who wrote (3166)4/9/2018 2:09:26 PM
From: scaram(o)uche  Respond to of 3202
RA.... I still do not understand the fast turnaround from the baricitinib CRL. Guess all will be clear on the 23rd.